Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer|a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
Interventions: DRUG: Durvalumab|DRUG: Olaparib|DRUG: Fulvestrant
Sponsor: UNICANCER
Collaborators: ARCAGY/ GINECO GROUP|SOLTI Breast Cancer Research Group